Chengbo Chen

Oct 7, 2024 | nature.com | Marcos Miranda |Chengbo Chen |Kaitlin R Sprouse |Adian Valdez

AbstractWe previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovioneTM.